180 related articles for article (PubMed ID: 7882727)
1. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
2. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
Guo Y; Xing Z
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
5. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
6. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
7. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
8. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
9. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of antitumor activity of tumor draining lymph node lymphocytes and peripheral blood lymphocytes in human oral cancer].
Guo W; Qiu WL; He RG
Zhonghua Kou Qiang Yi Xue Za Zhi; 1994 Nov; 29(6):336-8, 384. PubMed ID: 7743875
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer].
An W
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
Li D; Zhang X; Song Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
[TBL] [Abstract][Full Text] [Related]
14. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
[TBL] [Abstract][Full Text] [Related]
15. [An experimental study of the antitumor activity of tumor-infiltrating lymphocytes (TIL) in human tongue carcinoma in vitro].
Guo W
Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Sep; 27(5):259-61, 318. PubMed ID: 1306434
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
17. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2.
Liu X; Li D; Zhang C; Ba D; Liu J; Wan T; Li Z; Jin Y; He Y
Chin Med Sci J; 1993 Sep; 8(3):186-9. PubMed ID: 8142637
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
Xu ZY
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
[TBL] [Abstract][Full Text] [Related]
19. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
[TBL] [Abstract][Full Text] [Related]
20. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
Han B; Jia Y; Zhou M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
